* . *
  • About
  • Advertise
  • Privacy & Policy
  • Contact
Tuesday, June 17, 2025
Earth-News
  • Home
  • Business
  • Entertainment
    Elisabeth Moss’ ‘Handmaid’s Tale’ Emmy chances, by the numbers – Yahoo

    Elisabeth Moss’ ‘Handmaid’s Tale’ Emmy chances, by the numbers – Yahoo

    ‘Gangs of London’ Producer Explains Season 3 Deaths, Hypes Season 4 – Citizen Tribune

    Gangs of London’ Producer Reveals Shocking Season 3 Deaths and Teases Exciting Season 4

    The Iconic Missouri Diner That Gives You A Taste Of Live Entertainment With Your Meal – Yahoo

    Savor Delicious Meals While Enjoying Live Entertainment at Missouri’s Iconic Diner

    Keke Palmer Revealed How She Came Up With Her Son Leodis’ Name – Yahoo

    Keke Palmer Shares the Heartwarming Story Behind Her Son Leodis’ Name

    The Media and Entertainment Deal Machine Is Revving Up – WSJ

    The Media and Entertainment Deal Machine Is Gearing Up for Action

    Op-Ed: Data Storage and Protection in Today’s Media & Entertainment Industry – Sports Video Group

    How Data Storage and Protection Are Transforming the Media & Entertainment Industry

  • General
  • Health
  • News

    Cracking the Code: Why China’s Economic Challenges Aren’t Shaking Markets, Unlike America’s” – Bloomberg

    Trump’s Narrow Window to Spread the Truth About Harris

    Trump’s Narrow Window to Spread the Truth About Harris

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    Further Upside For Aeries Technology, Inc (NASDAQ:AERT) Shares Could Introduce Price Risks After 27% Bounce – simplywall.st

    Further Upside For Aeries Technology, Inc (NASDAQ:AERT) Shares Could Introduce Price Risks After 27% Bounce – simplywall.st

    Editor’s Pick: 9 Books on Technology – The Gospel Coalition

    9 Must-Read Books That Will Completely Transform How You Understand Technology

    New Semiconductor Technology Could Supercharge 6G Delivery – SciTechDaily

    Revolutionary Semiconductor Technology Set to Turbocharge 6G Connectivity

    UTC To Host Quantum Technology Workshop June 23-25 – Chattanoogan.com: Breaking News

    Join the Quantum Technology Workshop This June 23-25!

    Rimac Technology Powers the Bugatti Tourbillon with Cutting-Edge Battery and Powertrain Tech – Rimac Newsroom

    Rimac Technology Drives the Bugatti Tourbillon with Revolutionary Battery and Powertrain Innovation

    “Co-creation” boosts commercial technology for dual-use defense applications – Breaking Defense

    “Co-creation” boosts commercial technology for dual-use defense applications – Breaking Defense

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
  • Home
  • Business
  • Entertainment
    Elisabeth Moss’ ‘Handmaid’s Tale’ Emmy chances, by the numbers – Yahoo

    Elisabeth Moss’ ‘Handmaid’s Tale’ Emmy chances, by the numbers – Yahoo

    ‘Gangs of London’ Producer Explains Season 3 Deaths, Hypes Season 4 – Citizen Tribune

    Gangs of London’ Producer Reveals Shocking Season 3 Deaths and Teases Exciting Season 4

    The Iconic Missouri Diner That Gives You A Taste Of Live Entertainment With Your Meal – Yahoo

    Savor Delicious Meals While Enjoying Live Entertainment at Missouri’s Iconic Diner

    Keke Palmer Revealed How She Came Up With Her Son Leodis’ Name – Yahoo

    Keke Palmer Shares the Heartwarming Story Behind Her Son Leodis’ Name

    The Media and Entertainment Deal Machine Is Revving Up – WSJ

    The Media and Entertainment Deal Machine Is Gearing Up for Action

    Op-Ed: Data Storage and Protection in Today’s Media & Entertainment Industry – Sports Video Group

    How Data Storage and Protection Are Transforming the Media & Entertainment Industry

  • General
  • Health
  • News

    Cracking the Code: Why China’s Economic Challenges Aren’t Shaking Markets, Unlike America’s” – Bloomberg

    Trump’s Narrow Window to Spread the Truth About Harris

    Trump’s Narrow Window to Spread the Truth About Harris

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    Further Upside For Aeries Technology, Inc (NASDAQ:AERT) Shares Could Introduce Price Risks After 27% Bounce – simplywall.st

    Further Upside For Aeries Technology, Inc (NASDAQ:AERT) Shares Could Introduce Price Risks After 27% Bounce – simplywall.st

    Editor’s Pick: 9 Books on Technology – The Gospel Coalition

    9 Must-Read Books That Will Completely Transform How You Understand Technology

    New Semiconductor Technology Could Supercharge 6G Delivery – SciTechDaily

    Revolutionary Semiconductor Technology Set to Turbocharge 6G Connectivity

    UTC To Host Quantum Technology Workshop June 23-25 – Chattanoogan.com: Breaking News

    Join the Quantum Technology Workshop This June 23-25!

    Rimac Technology Powers the Bugatti Tourbillon with Cutting-Edge Battery and Powertrain Tech – Rimac Newsroom

    Rimac Technology Drives the Bugatti Tourbillon with Revolutionary Battery and Powertrain Innovation

    “Co-creation” boosts commercial technology for dual-use defense applications – Breaking Defense

    “Co-creation” boosts commercial technology for dual-use defense applications – Breaking Defense

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
Earth-News
No Result
View All Result
Home Health

Adapted CAR-T Therapy Shows Promise in Myasthenia Gravis

July 8, 2023
in Health
Adapted CAR-T Therapy Shows Promise in Myasthenia Gravis
Share on FacebookShare on Twitter

The first study to use an RNA-based chimeric antigen receptor T-cell (rCAR-T) therapy in autoimmune disease showed people with generalized myasthenia gravis tolerated the treatment well and experienced improvements in disease severity scales.

In the phase Ib/II MG-001 trial, no study-related serious adverse events or cases of dose-limiting toxicity, cytokine release syndrome, or neurotoxicity emerged in any of 14 participants, reported James Howard Jr., MD, of the University of North Carolina in Chapel Hill, and co-authors.

Although four participants developed fevers, all resolved within 24 hours of infusion and were not associated with cytokine release syndrome, the researchers wrote in Lancet Neurology.

Mean improvements from baseline to week 12 were seen on four validated scales, including:

6 points on Myasthenia Gravis-Activities of Daily Living (MG-ADL) score7 points on Quantitative Myasthenia Gravis (QMG) score14 points on Myasthenia Gravis Composite (MGC) score9 points on Myasthenia Gravis Quality of Life 15-revised (MG-QoL-15r) score

A 2-point change on the MG-ADL and a 3-point change in QMG and MGC are considered clinically meaningful, Howard and colleagues noted. No consensus exists as to what is considered a clinically meaningful change in the MG-QoL-15r, they added.

MG-001 was an open label, phase Ib/IIa trial that studied the autologous anti-B-cell maturation antigen (BCMA) rCAR-T therapy Descartes-08 in adults with generalized myasthenia gravis.

In the phase Ib dose-finding portion of the study, three patients with Myasthenia Gravis Foundation of America (MGFA) class III-IV disease received three increasing doses of Descartes-08 to determine a maximum tolerated dose. During phase IIa, 11 patients with MGFA class II-IV disease received six doses at the maximum tolerated dose in an outpatient setting.

DNA-based CAR-T therapies, which become a permanent part of the T-cell genome and replicate with each cell division, are used successfully to treat various advanced hematological cancers. But their often-severe toxicities and pre-treatment requirements for lymphodepleting chemotherapy have limited their use to the oncology setting.

Within autoimmune disease indications, patients with severe forms of systemic lupus erythematosus and neuromyelitis optica have received DNA-based CAR T-cell therapies, the authors noted. Their use has been limited to clinical studies and has required extensive inpatient-based monitoring.

In MG-001, the investigators engineered the cells with RNA, rather than DNA, “on the premise that the temporary, non-replicable influence of mRNA would confer predictable pharmacokinetics and consequently a more favorable safety profile,” Howard and co-authors wrote, noting that these advances in RNA engineering were the same that enabled the widespread use of mRNA in vaccines.

“The elegant RNA-based approach to CAR T cells used by these investigators has the advantage over standard DNA-based CAR T-cell therapy, that potentially harmful lymphodepletion chemotherapy is not required for rCAR-T engineering,” wrote Andreas Meisel, MD, of Charité Universitaetsmedizin Berlin, in an accompanying editorial.

“A major finding is the feasibility of producing rCAR-T from patients with generalized myasthenia gravis treated by standard immunosuppressive therapies,” he added.

Each study patient had previously received at least one dose of intravenous immunoglobulin, corticosteroids, non-steroidal immune suppressants, or plasma exchange. Despite the use of immunosuppressants, the investigators were able to produce Descartes-08 cells from all participants, with a potency similar to that from a healthy volunteer.

Howard and co-authors recorded that CAR RNA was detected in participants’ peripheral blood only at 1 to 2 hours after infusion, noting that this finding supported the feasibility of using rCAR-T therapies in the outpatient setting.

“Although DNA-based CAR T-cell therapies are also moving to the outpatient setting, they still require close monitoring after infusion, with daily clinic visits and reservation of hospital beds in case severe toxicities develop,” they wrote. “In accordance with time-restricted expression of RNA-based CAR molecules in vitro, mRNA detection in our study was transient.”

The MG-001 trial has broader implications, suggested Meisel: “Myasthenia gravis can serve as a model disease for exploring this innovative therapeutic approach, which is also of great interest for other autoantibody-mediated neurological diseases, such as autoimmune encephalitis.”

The study had several limitations, the authors acknowledged, including its small size and the fact that it was unblinded. An ongoing phase IIb part of the MG-001 trial has a targeted enrollment of 30 patients and includes a placebo group.

Disclosures

This study was funded by Cartesian Therapeutics and the National Institute of Neurological Disorders and Stroke.

Howard reported relationships with Alexion Pharmaceuticals, argenx, Cartesian Therapeutics, CDC, Myasthenia Gravis Foundation of America, Muscular Dystrophy Association, NIH, the Patient-Centered Outcomes Research Institute, UCB, Takeda Pharmaceuticals, Immunovant, NMD Pharma, Novartis Pharmaceuticals, Regeneron Pharmaceuticals, Sanofi, Horizon Therapeutics, and Toleranzia. Co-authors reported numerous relationships with pharmaceutical companies and nonprofit organizations.

Meisel reported relationships with Alexion Pharmaceuticals, Argenx, Axunio, Desitin, Grifols, Hormosan Pharma, Janssen, Merck, Octapharma, UCB, Xcenda, and the German Myasthenia Gravis Society.

Primary Source

The Lancet Neurology

Source Reference: Granit V, et al “Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): A prospective, multicentre, open-label, non-randomised phase 1b/2a study” Lancet Neurol 2023; DOI: 10.1016/S1474-4422(23)00194-1.

Secondary Source

The Lancet Neurology

Source Reference: Meisel A “Are CAR T cells the answer to myasthenia gravis therapy?” Lancet Neurol 2023; DOI: 10.1016/S1474-4422(23)00211-9.

>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : MedPageToday – https://www.medpagetoday.com/neurology/generalneurology/105387

Tags: AdaptedCAR-Thealth
Previous Post

Why the Next Big Hope for Alzheimer’s Might Not Help Most Black Patients

Next Post

Top Misconceptions About Heat Illness, From an EMT in the Hottest Place on Earth

Safran and Bombardier announce defense technology innovation partnership – Safran

Safran and Bombardier Join Forces to Revolutionize Defense Technology

June 16, 2025
Bee-lieve the buzz: Honeybees help Delaware agriculture, ecology – Bay to Bay News

Bee-lieve the buzz: Honeybees help Delaware agriculture, ecology – Bay to Bay News

June 16, 2025
NCSE welcomes Britt Miller – National Center for Science Education

NCSE welcomes Britt Miller – National Center for Science Education

June 16, 2025
Science is on the federal chopping block and North Carolinians will suffer – NC Newsline

Federal Science Funding Slashed: How North Carolinians Will Be Impacted

June 16, 2025
Does yard work count as exercise? UI expert provides tips to maintain a healthy lifestyle during busy summer months – Iowa Now

Is Yard Work Really Exercise? Expert Tips for Staying Healthy During Busy Summer Months

June 16, 2025
Insurers must promote the blue economy – Eco-Business

Insurers must promote the blue economy – Eco-Business

June 16, 2025
Elisabeth Moss’ ‘Handmaid’s Tale’ Emmy chances, by the numbers – Yahoo

Elisabeth Moss’ ‘Handmaid’s Tale’ Emmy chances, by the numbers – Yahoo

June 16, 2025
Tariffs Are Driving 2026 Health Insurance Premiums Up – KFF

Tariffs Are Driving 2026 Health Insurance Premiums Up – KFF

June 16, 2025
Minnesota, Known for Bipartisan Civility, Reels After Attack on Lawmakers – The New York Times

Minnesota, Known for Bipartisan Civility, Reels After Attack on Lawmakers – The New York Times

June 16, 2025
FDA Grants Sarepta Therapeutics Platform Technology Designation to Expedite Gene Therapy Reviews – geneonline.com

FDA Accelerates Gene Therapy Reviews with Breakthrough Platform Technology for Sarepta Therapeutics

June 16, 2025

Categories

Archives

June 2025
MTWTFSS
 1
2345678
9101112131415
16171819202122
23242526272829
30 
« May    
Earth-News.info

The Earth News is an independent English-language daily published Website from all around the World News

Browse by Category

  • Business (20,132)
  • Ecology (689)
  • Economy (703)
  • Entertainment (21,606)
  • General (15,413)
  • Health (9,744)
  • Lifestyle (708)
  • News (22,149)
  • People (705)
  • Politics (710)
  • Science (15,921)
  • Sports (21,202)
  • Technology (15,689)
  • World (683)

Recent News

Safran and Bombardier announce defense technology innovation partnership – Safran

Safran and Bombardier Join Forces to Revolutionize Defense Technology

June 16, 2025
Bee-lieve the buzz: Honeybees help Delaware agriculture, ecology – Bay to Bay News

Bee-lieve the buzz: Honeybees help Delaware agriculture, ecology – Bay to Bay News

June 16, 2025
  • About
  • Advertise
  • Privacy & Policy
  • Contact

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

Go to mobile version